{"id":146827,"date":"2026-04-30T13:13:26","date_gmt":"2026-04-30T17:13:26","guid":{"rendered":"https:\/\/medcitynews.com\/?p=146827"},"modified":"2026-04-30T19:32:34","modified_gmt":"2026-04-30T23:32:34","slug":"avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln","status":"publish","type":"post","link":"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/","title":{"rendered":"Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials"},"content":{"rendered":"

The few drugs available for lung disorders that cause scarring of the organ are pills that circulate throughout the body. Avalyn Pharma is aiming for a better effect with inhalable medicines, and the company now has $300 million to show that benefit through ongoing clinical trials.<\/p>\n

Investors are buying into Avalyn\u2019s strategy. Late Wednesday, the company offered 16.6 million shares\u2014 about 4.8 million more than it planned in preliminary IPO terms<\/a>. Avalyn priced those shares at $18 each<\/a>, which was the top of the targeted price range. Avalyn\u2019s shares will trade on the Nasdaq under the stock symbol \u201cAVLN.\u201d<\/p>\n

Boston-based Avalyn is developing drugs for two types of pulmonary fibrosis, a disorder that leads to lung inflammation and the development of scar tissue, a pathological process called fibrosis. In idiopathic pulmonary fibrosis (IPF), the cause of fibrosis is unknown. In progressive pulmonary fibrosis (PPF), the cause can be attributed to something such as an autoimmune disease or exposure to allergens.<\/p>\n

The standard of care for IPF includes two older products: pirfenidone, a former Roche drug<\/a> marketed as Esbriet, and nintedanib, which Boehringer Ingelheim markets as Ofev. Each oral small molecule blocks a different protein associated with lung disorders. Both achieved blockbuster status, but generic versions are now eroding revenue and market share. Last fall, Boehringer received FDA approval for new IPF drug nerandomilast, brand name Jascayd<\/a>, introducing yet another approach to the disease.<\/p>\n

While the oral drugs aren\u2019t cures for pulmonary fibrosis, they can slow its progression. But one problem with these pills is the wide range of side effects they cause as these small molecules circulate throughout the body. Nausea and diarrhea are common. In the Ofev studies, cardiovascular problems were reported. Side effect and tolerability issues lead many patients to reduce or interrupt dosing. In the IPO filing<\/a>, Avalyn said just 30% of IPF patients are actively treated with antifibrotic medications and 50% of patients discontinue them within a year of starting treatment.<\/p>\n

Avalyn drug AP01 is an inhalable version of pirfenidone; AP02 is an inhalable formulation of nintedanib. A third Avalyn drug, AP03, is an inhalable fixed-dose combination of pirfenidone and nintedanib. These drugs are administered via a proprietary nebulizer device. Inhalable formulations enable lower dosing than what\u2019s required for oral administration, which should further reduce side effect and tolerability problems.<\/p>\n

\u201cBy delivering drugs directly to the lungs, our approach is designed to fundamentally improve the benefit-risk profile of antifibrotic therapy by achieving higher drug concentration at the site of disease while substantially reducing systemic exposure,\u201d Avalyn said in the filing. \u201cWe believe this lung-targeted delivery strategy enables sustained long-term treatment, addressing key limitations of existing systemic therapies and supporting better treatment adherence and long-term disease management for patients with pulmonary fibrosis.\u201d<\/p>\n

In Phase 1 testing, both AP01 and AP02 showed low systemic exposure and a favorable side effect profile. Both drugs are currently in mid-stage clinical development. Enrollment in a Phase 2b test of AP01 is expected to be complete by the middle of this year; preliminary data are expected in the second half of next year. Enrollment of the Phase 2 test of AP02 is expected to finish in the second half of 2027 followed by preliminary data late that year.<\/p>\n

Companies with novel IPF drugs in the clinic include Bristol Myers Squibb, Contineum Therapeutics, Endeavor Biomedicines, Insilico Medicine, and Insmed. Avalyn does not view them as direct competitors. In its IPO filing, the company noted that clinical tests of these drugs are allowing patients to continue taking background oral antifibrotic drugs. Avalyn believes its drugs, new formulations of those older background medications, would become new background therapies that could be used alongside those novel ones.<\/p>\n

\u201cIn the future, we envision any approved novel mechanism of action to be used in combination with our inhaled background standard of care,\u201d the company said in the filing. \u201cGiven these factors, we believe that our portfolio is advantageously positioned relative to competitive agents on the market or in clinical development.\u201d<\/p>\n

In its history prior to the IPO, Avalyn had raised $389 million from life science investors, the company said in the filing. The most recent financing was a $100 million Series D round<\/a> last July led by Survetta Capital Management and SR One. Following the IPO, the largest stockholder is Novo Holdings with a 7.96% post-IPO stake, followed by SR One\u2019s 6.58% stake, the filing shows.<\/p>\n

As of the end of 2025, Avalyn reported its cash position was $138.3 million. Now that the company has infused its coffers with IPO money, it plans to spend $150 million on AP01 and $90 million on AP02, continuing their mid-stage studies and advancing both drugs to Phase 3 development. Another $10 million is budgeted for starting Phase 1 testing of AP03. Avalyn said it expects its capital will be enough to support the company into 2029.<\/p>\n

Photo: Cavallini James\/BSIP\/Education Images\/Universal Images Group, via Getty Images<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Avalyn Pharma found strong investor interest in its inhalable drugs in development for two types of pulmonary fibrosis, enabling the company to upsize its IPO. Data from two mid-stage studies are expected in 2027. <\/p>\n","protected":false},"author":25932,"featured_media":10674,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"featured_image_focal_point":[],"homepage_placement":"top","homepage_placements":{"top":true,"featured":true,"sidebar":false},"homepage_alternative_layout":false,"featured_categories":[54,69],"hide_from_feed":false,"footnotes":""},"categories":[69,54],"tags":[49192,42355,34071,12102,32655,16902,7758,22413],"class_list":["post-146827","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-pharma-channel","tag-avalyn-pharma","tag-biopharma-nl","tag-biotech-ipo","tag-clinical-trials","tag-fibrosis","tag-idiopathic-pulmonary-fibrosis","tag-investing","tag-respiratory"],"acf":[],"yoast_head":"\nAvalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials - MedCity News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials - MedCity News\" \/>\n<meta property=\"og:description\" content=\"Avalyn Pharma found strong investor interest in its inhalable drugs in development for two types of pulmonary fibrosis, enabling the company to upsize its IPO. Data from two mid-stage studies are expected in 2027.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/\" \/>\n<meta property=\"og:site_name\" content=\"MedCity News\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T17:13:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-30T23:32:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/04\/GettyImages-1255228377.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"848\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Frank Vinluan\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@frankvinluan\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Frank Vinluan\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/\"},\"author\":{\"name\":\"Frank Vinluan\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"headline\":\"Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials\",\"datePublished\":\"2026-04-30T17:13:26+00:00\",\"dateModified\":\"2026-04-30T23:32:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/\"},\"wordCount\":816,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/04\/GettyImages-1255228377.jpg\",\"keywords\":[\"Avalyn Pharma\",\"biopharma nl\",\"biotech IPO\",\"Clinical Trials\",\"fibrosis\",\"idiopathic pulmonary fibrosis\",\"investing\",\"respiratory\"],\"articleSection\":[\"BioPharma\",\"Pharma\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/\",\"url\":\"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/\",\"name\":\"Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials - MedCity News\",\"isPartOf\":{\"@id\":\"https:\/\/medcitynews.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/04\/GettyImages-1255228377.jpg\",\"datePublished\":\"2026-04-30T17:13:26+00:00\",\"dateModified\":\"2026-04-30T23:32:34+00:00\",\"author\":{\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\"},\"breadcrumb\":{\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/#primaryimage\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/04\/GettyImages-1255228377.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/04\/GettyImages-1255228377.jpg\",\"width\":1024,\"height\":848},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medcitynews.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medcitynews.com\/#website\",\"url\":\"https:\/\/medcitynews.com\/\",\"name\":\"MedCity News\",\"description\":\"Healthcare technology news, life science current events\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medcitynews.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35\",\"name\":\"Frank Vinluan\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medcitynews.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"contentUrl\":\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg\",\"caption\":\"Frank Vinluan\"},\"description\":\"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/frankvinluan\/\",\"https:\/\/x.com\/frankvinluan\"],\"url\":\"https:\/\/medcitynews.com\/author\/fvinluan\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials - MedCity News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/","og_locale":"en_US","og_type":"article","og_title":"Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials - MedCity News","og_description":"Avalyn Pharma found strong investor interest in its inhalable drugs in development for two types of pulmonary fibrosis, enabling the company to upsize its IPO. Data from two mid-stage studies are expected in 2027.","og_url":"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/","og_site_name":"MedCity News","article_published_time":"2026-04-30T17:13:26+00:00","article_modified_time":"2026-04-30T23:32:34+00:00","og_image":[{"width":1024,"height":848,"url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/04\/GettyImages-1255228377.jpg","type":"image\/jpeg"}],"author":"Frank Vinluan","twitter_card":"summary_large_image","twitter_creator":"@frankvinluan","twitter_misc":{"Written by":"Frank Vinluan","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/#article","isPartOf":{"@id":"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/"},"author":{"name":"Frank Vinluan","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"headline":"Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials","datePublished":"2026-04-30T17:13:26+00:00","dateModified":"2026-04-30T23:32:34+00:00","mainEntityOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/"},"wordCount":816,"commentCount":0,"image":{"@id":"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/04\/GettyImages-1255228377.jpg","keywords":["Avalyn Pharma","biopharma nl","biotech IPO","Clinical Trials","fibrosis","idiopathic pulmonary fibrosis","investing","respiratory"],"articleSection":["BioPharma","Pharma"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/","url":"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/","name":"Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials - MedCity News","isPartOf":{"@id":"https:\/\/medcitynews.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/#primaryimage"},"image":{"@id":"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/#primaryimage"},"thumbnailUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/04\/GettyImages-1255228377.jpg","datePublished":"2026-04-30T17:13:26+00:00","dateModified":"2026-04-30T23:32:34+00:00","author":{"@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35"},"breadcrumb":{"@id":"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/#primaryimage","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/04\/GettyImages-1255228377.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/04\/GettyImages-1255228377.jpg","width":1024,"height":848},{"@type":"BreadcrumbList","@id":"https:\/\/medcitynews.com\/2026\/04\/avalyn-pharma-ipo-idiopathic-progressive-pulmonary-fibrosis-ipf-ppf-avln\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medcitynews.com\/"},{"@type":"ListItem","position":2,"name":"Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials"}]},{"@type":"WebSite","@id":"https:\/\/medcitynews.com\/#website","url":"https:\/\/medcitynews.com\/","name":"MedCity News","description":"Healthcare technology news, life science current events","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medcitynews.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/327ad000c78d52bed5e2ed77a994ce35","name":"Frank Vinluan","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medcitynews.com\/#\/schema\/person\/image\/","url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","contentUrl":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2023\/05\/cropped-FrankVinluan_headshot-96x96.jpg","caption":"Frank Vinluan"},"description":"Frank Vinluan is senior biopharma reporter for MedCity News. He previously held business reporting positions at Xconomy, The Seattle Times, The Des Moines Register, and the Triangle Business Journal. LinkedIn: https:\/\/www.linkedin.com\/in\/frankvinluan\/ Twitter: @frankvinluan","sameAs":["https:\/\/www.linkedin.com\/in\/frankvinluan\/","https:\/\/x.com\/frankvinluan"],"url":"https:\/\/medcitynews.com\/author\/fvinluan\/"}]}},"_links":{"self":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146827","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/users\/25932"}],"replies":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/comments?post=146827"}],"version-history":[{"count":3,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146827\/revisions"}],"predecessor-version":[{"id":146840,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/posts\/146827\/revisions\/146840"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media\/10674"}],"wp:attachment":[{"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/media?parent=146827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/categories?post=146827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medcitynews.com\/wp-json\/wp\/v2\/tags?post=146827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}